ClinicalTrials.gg
TerminatedNCT01571635Updated Jun 18, 2023Results posted

Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia.

A Phase 2 interventional study of SOTATERCEPT (ACE-011) in Beta Thalassemia Major and Beta Thalassemia Intermedia, sponsored by Celgene. Terminated at 18 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-18.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Why this study was terminated
Business objectives have changed

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
46
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in beta-Thalassemia by Bristol-Myers Squibb — 3 open to participants now, 5 under way, 1 of them phase 3. beta-Thalassemia · Bristol-Myers Squibb.

Started
2012
the only one that year
Phase 2
4 of 14
1 open now
Registered
3rd of 14
by date

Among the 14 studies in beta-Thalassemia by Bristol-Myers Squibb, this one is the only one that started in 2012, is one of 4 in phase 2, and was the 3rd registered.

beta-Thalassemia

294 studies on the registry are indexed under beta-Thalassemia; 69 are open to participants now.

Browse beta-Thalassemia studies →

Open to participants now

3 of the 14 studies in beta-Thalassemia by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 43 beta-Thalassemia studies recruiting now, 10 (23%) set no upper age limit and 31 (72%) stop at 75 or younger; 34 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in beta-Thalassemia by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

Dose finding study to determine the safety and tolerability of Sotatercept (ACE-011) in adults with Beta (β)-Thalassemia

03

Conditions studied

  • Beta Thalassemia Major
  • Beta Thalassemia Intermedia

Browse trials for

Keywords

  • Beta-Thalassaemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women 18 years of age at the time of signing the document with a diagnosis of β-thalassemia major (including all subtypes) or β-thalassemia intermedia.
  • For transfusion dependent subjects: permanent transfusion dependency is defined as requiring packed red blood cells (pRBCs) and iron chelation therapy:

    • Average transfusion requirement of at least 2 units/30 days of pRBCs (Gale, 2011) confirmed for a minimum of 168 days (six months) immediately preceding enrollment (study Day 1, first Dose);
    • No transfusion-free period of more than 45 consecutive days during the 168 days immediately preceding enrollment (study Day 1, first Dose);
    • Prior transfusion levels ≤ 10.5 g/dL.
  • For non-transfusion dependent subjects: non-transfusion dependency is defined as a transfusion free for a minimum of 168 days immediately preceding enrollment (study Day 1, first Dose), with the exception of ≤ to one episode of transfusion in the period of a minimum of 168 days immediately preceding enrollment (study Day 1, first Dose) (One episode of transfusion is defined as ≤ 4 transfusion units administered, occurred within 42 days [first transfusion is counted as day 1] due to concurrent illness [e.g. infection], [Guidelines Clin Management of Thalassaemia, 2008]). (This inclusion criteria is not valid for France).
  • Performance status: (ECOG) score of 0 to 1
  • No concurrent severe hepatic disease:

    • (AST) or Alanine Transaminase (ALT) no greater than 3 x (ULN);
    • Albumin ≥ 3 g/dL.
  • Serum creatinine ≤ 1.5 x ULN.
  • Females of participating in the study are to use highly effective methods of during study participation and for 112 days (approximately five times the mean terminal half-life of sotatercept [23 days] based on multiple-dose PK data) following the last dose of sotatercept. FCBP must have a negative serum beta Human Chorionic Gonadotropin (β-HCG) pregnancy test within three days of Sotatercept dosing (Day 1). Subjects must be counseled concerning measures to be used to prevent pregnancy and potential toxicities prior to the first dose of sotatercept. A FCBP is a sexually mature woman who has not undergone a hysterectomy or bilateral oophorectomy or who has not been for at least 24 consecutive months (i.e., who has had menses at some time in the preceding 24 months).
  • Males must agree to use a latex condom during any sexual contact with FCBSs while participating in the study and for 112 days following the last dose of Sotatercept, even if he has undergone a successful vasectomy. Subjects must be counseled concerning measures to be used to prevent pregnancy and potential toxicities prior to the first dose of sotatercept.
  • Agreement to adhere to the study visit schedule, understand and comply with all protocol requirements.
  • Understand and provide written informed consent.

Exclusion criteria

Exclusion Criteria:

  • Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing participating in the study.
  • Evidence of active antibody (HCV), surface antigen (HBsAg and HB core Ab), or (HIV) antibody.
  • Known history of thromboembolic events ≥ Grade 3 according to National Cancer Institute (NCI CTCAE) version 4.0 (current active minor version).
  • Subjects with insulin dependent diabetes.
  • Subjects with major cardiac problems such as:

    • Major risk of heart failure, confirmed with myocardiac T2* ≤ 10 ms. Myocardiac T2* performed in the last one and a half years prior to subject enrollment (study Day 1, first Dose) will be considered valid.
    • Cardiac arrhythmia which requires treatment (i.e. atrial fibrillation).
  • Treatment with another drug or device \< 28 days prior to study entry.
  • Use of an Erythropoiesis Stimulating Agent (ESA) within the 28 days prior to enrollment (study Day 1, first Dose).
  • Subjects on hydroxyurea treatment for which the dose was changed in the last one year prior to subject enrollment (study Day 1, first Dose).
  • Subjects on anticoagulant therapy, such as warfarin.
  • Subjects who started bisphosphonates within the last three months prior to subject enrollment (study Day 1, first Dose).
  • Pregnant or lactating females.
  • Uncontrolled hypertension. Controlled hypertension for this protocol is considered ≤ Grade 1 according to NCI CTCAE version 4.0 (current active minor version) (Appendix B).
  • A history of major organ damage including:

    • Liver disease with > 3x or histopathological evidence of liver cirrhosis on liver ;
    • Heart disease with ≥ Grade 2 according to NCI CTCAE version 4.0 (current active minor version);
    • Kidney disease with a calculated \< 40 mL/min (Cockcroft-Gault formula);
    • Pulmonary fibrosis or pulmonary hypertension as confirmed by a specialist.
  • Adrenal insufficiency.
  • Heart failure as classified by the (NYHA) classification of 3 or higher (Appendix C).
  • Major surgery within 30 days prior to study Day 1 (subjects must have completely recovered from any previous surgery prior to study Day 1).
  • History of severe allergic or anaphylactic reactions or to recombinant proteins or in the Investigational Product (see Investigator Brochure).
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Sotatercept dose level 0.1mg/kg

    Experimental 0.1 mg/kg -Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period

    Drug: SOTATERCEPT (ACE-011)

  • Experimental
    Sotatercept dose level 0.3mg/ kg

    Experimental 0.3 mg/kg - Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period

    Drug: SOTATERCEPT (ACE-011)

  • Experimental
    Sotatercept dose level 0.5mg/kg

    Experimental 0.5 mg/kg -Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period

    Drug: SOTATERCEPT (ACE-011)

  • Experimental
    Sotatercept dose level 0.75mg/kg

    Experimental 0.75 mg/kg - Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period

    Drug: SOTATERCEPT (ACE-011)

  • Experimental
    Sotatercept dose level 1.0mg/kg

    Experimental 1.0 mg/kg -Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period

    Drug: SOTATERCEPT (ACE-011)

  • Experimental
    Sotatercept dose level 1.5mg/kg

    Experimental 1.5 mg/kg -Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period

    Drug: SOTATERCEPT (ACE-011)

Interventions

  • 0.1 mg/kg to 1.5mg/kg Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period.

    Also known as: (ACE-011)

06

What researchers measure

Primary outcomes

  1. Potential Recommended Dose as Determined by Number of Participants Experiencing Dose-Limiting Toxicities and Recommended Dose

    Number of participants with dose-limiting toxicities (DLT) are used to determine the potential recommended dose (PRD). PRD is defined as the highest dose with up to 1 out of 6 patients experiencing a DLT. DLT is defined as any side effects of the study treatment serious enough to prevent an increase in dose or level of treatment, including at least one of the following: Hypertension ≥ Grade 3 per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0; Hgb \> 14 g/dL sustained for four weeks; any NCI CTCAE toxicity ≥ Grade 3. Grade 3 is defined as severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily life. PRD was identified as 1 mg/kg. Due to study termination, no patients were enrolled after 1 mg/kg cohort or in the Expansion Cohort. Thus, primary analyses to determine recommended dose (RD) were not conducted.

    Time frame: From first dose up to 28 days post the first dose

Secondary outcomes

  1. Number of Participants With Red Blood Cell Transfusion Burden Reduction From Baseline During Treatment

    Transfusion burden at baseline is defined as the total number of units of RBC transfusions that participants received within 168 days (24 weeks) prior to the first dose of study therapy. Transfusion burden during treatment is defined as the total number of RBC transfusion units that each participant received during the treatment divided by the treatment duration and multiplied by 168 days. The result is a 168-day transfusion burden average. Baseline measurement includes RBC transfusion history for transfusion dependent and non-transfusion dependent participants, starting at 168 days prior to enrollment.

    Time frame: From baseline to the last dose of study treatment (up to approximately 112 months)

  2. Number of Participants With Hemoglobin Level Increase From Baseline in Non-Transfusion Dependent B-Thalassemia Intermedia Participants

    The Number of participants with a change in Hemoglobin levels will be listed for non-RBC transfusion dependent participants. Baseline assessments are the average of the last two measurements prior to the start of therapy.

    Time frame: Measurements were taken in 9 and 12-week intervals, from baseline up to approximately 112 months

  3. Number of Participants Experiencing Adverse Events (AEs)

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal. Treatment emergent adverse events (TEAE) are defined as an AE that began after the start of trial medication treatment; or if the event was continuous from baseline and was serious, trial medication-related, or resulted in death, discontinuation, or interruption or reduction of trial therapy.

    Time frame: From first dose up to 112 days after the last dose of study treatment (up to 115 months)

  4. Concentrations of Sotatercept in Serum

    Sotatercept was administered as a subcutaneous injection every 21 days during the Treatment Period. Pharmacokinetic (PK) samples were collected at the pre-specified timepoints.

    Time frame: Dose 1, Day 8; Dose 1, Day 15; Dose 2, Day 1; Dose 2, Day 8; Dose 3, Day 1; Dose 3, Day 8; Dose 4, Day 1; Dose 5, Day 1; Dose 6, Day 1

  5. Number of Participants With Anti-Drug Antibody (ADA)

    The number of participants with Anti-Sotatercept Antibody is a summary of antidrug antibody (ADA) status for ADA-evaluated participants. A participant is counted as 'positive' if there is any positive result captured during the study, a participant is counted as 'negative' if there is no positive result captured during the study. ADA data was collected Day 1 in dose schedules 1 through 6. Starting from Dose 7, ADA was measured at Day 1 every 3 Doses, then finally at the post-treatment follow-up visit at Month 2 and Month 4.

    Time frame: From first dose up to 4 months after last dose (up to approximately 116 months)

  6. Number of Participants Experiencing Quality of Life (QOL) Change From Baseline

    The number of participants in the expansion cohort experiencing changes from baseline in Quality of Life. QOL was planned to be assessed at Day 168 (6 months) and Day 336 (12 months), after Dose 1 Day 1, independent of Dose Delay for participants enrolled in the Expansion Cohort only. QOL was planned to be calculated using the SF-36 and the FACT Anemia. The SF-36 is a Medical Outcomes Study (MOS) consisting of 36 questions developed to determine health status. The SF-36 measures eight scales: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The FACT Anemia measures fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) Measurement System. Due to early study termination, no participants were enrolled in the expansion cohort and QOL was not assessed.

    Time frame: From pre-dose up to Dose 8 (168 days/6months) and Dose 16 (336 days/12months) only

07

Results

Posted Jun 18, 2023
Limitations and caveats
Sotatercept development in β-thalassemia indication was stopped and no further patients were enrolled after 1 mg/kg cohort was completed. Due to the early termination of the study and no enrollment of the Expansion Cohort, the primary analyses to determine the recommended dose (RD) and the secondary analysis of QoL change from baseline were not conducted.

Participant flow

Participant flow — Overall Study
MilestoneDose Level 1a: 0.1 mg/kgDose Level 1b: 0.3 mg/kgDose Level 2: 0.5 mg/kgDose Level 3: 0.75 mg/kgDose Level 4: 1 mg/kg
Started898129
Completed21100
Not completed687129
Withdrew: Adverse event30235
Withdrew: Other reasons21221
Withdrew: Study terminated by sponsor04131
Withdrew: Withdrew consent11230
Withdrew: Lack of efficacy02012

Outcome measures

PrimaryPotential Recommended Dose as Determined by Number of Participants Experiencing Dose-Limiting Toxicities and Recommended Dose

Number of participants with dose-limiting toxicities (DLT) are used to determine the potential recommended dose (PRD). PRD is defined as the highest dose with up to 1 out of 6 patients experiencing a DLT. DLT is defined as any side effects of the study treatment serious enough to prevent an increase in dose or level of treatment, including at least one of the following: Hypertension ≥ Grade 3 per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0; Hgb \> 14 g/dL sustained for four weeks; any NCI CTCAE toxicity ≥ Grade 3. Grade 3 is defined as severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily life. PRD was identified as 1 mg/kg. Due to study termination, no patients were enrolled after 1 mg/kg cohort or in the Expansion Cohort. Thus, primary analyses to determine recommended dose (RD) were not conducted.

Time frame:
From first dose up to 28 days post the first dose
Reported as:
Count of participants · Participants
Potential Recommended Dose as Determined by Number of Participants Experiencing Dose-Limiting Toxicities and Recommended Dose
ParticipantsDose Level 1a: 0.1 mg/kgDose Level 1b: 0.3 mg/kgDose Level 2: 0.5 mg/kgDose Level 3: 0.75 mg/kgDose Level 4: 1 mg/kg
Potential Recommended Dose as Determined by Number of Participants Experiencing Dose-Limiting Toxicities and Recommended Dose00000
SecondaryNumber of Participants With Red Blood Cell Transfusion Burden Reduction From Baseline During Treatment

Transfusion burden at baseline is defined as the total number of units of RBC transfusions that participants received within 168 days (24 weeks) prior to the first dose of study therapy. Transfusion burden during treatment is defined as the total number of RBC transfusion units that each participant received during the treatment divided by the treatment duration and multiplied by 168 days. The result is a 168-day transfusion burden average. Baseline measurement includes RBC transfusion history for transfusion dependent and non-transfusion dependent participants, starting at 168 days prior to enrollment.

Time frame:
From baseline to the last dose of study treatment (up to approximately 112 months)
Reported as:
Count of participants · Participants
Number of Participants With Red Blood Cell Transfusion Burden Reduction From Baseline During Treatment
ParticipantsDose Level 1a: 0.1 mg/kgDose Level 1b: 0.3 mg/kgDose Level 2: 0.5 mg/kgDose Level 3: 0.75 mg/kgDose Level 4: 1 mg/kg
≥ 25% reduction00243
≥ 33% reduction00231
≥ 50% reduction00120
SecondaryNumber of Participants With Hemoglobin Level Increase From Baseline in Non-Transfusion Dependent B-Thalassemia Intermedia Participants

The Number of participants with a change in Hemoglobin levels will be listed for non-RBC transfusion dependent participants. Baseline assessments are the average of the last two measurements prior to the start of therapy.

Time frame:
Measurements were taken in 9 and 12-week intervals, from baseline up to approximately 112 months
Reported as:
Count of participants · Participants
Number of Participants With Hemoglobin Level Increase From Baseline in Non-Transfusion Dependent B-Thalassemia Intermedia Participants
ParticipantsDose Level 1a: 0.1 mg/kgDose Level 1b: 0.3 mg/kgDose Level 2: 0.5 mg/kgDose Level 3: 0.75 mg/kgDose Level 4: 1 mg/kg
9-week episode with Hgb ≥ 1.0 g/dl change from baseline (non-transfusion dependent participants)05462
9-week episode with Hgb ≥ 1.5 g/dl change from baseline (non-transfusion dependent participants)02261
12-Week episode with Hgb ≥ 1.0 g/dl change from baseline (non-transfusion dependent participants)04461
12-Week episode with Hgb ≥ 1.5 g/dl change from baseline (non-transfusion dependent participants)02261
SecondaryNumber of Participants Experiencing Adverse Events (AEs)

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal. Treatment emergent adverse events (TEAE) are defined as an AE that began after the start of trial medication treatment; or if the event was continuous from baseline and was serious, trial medication-related, or resulted in death, discontinuation, or interruption or reduction of trial therapy.

Time frame:
From first dose up to 112 days after the last dose of study treatment (up to 115 months)
Reported as:
Count of participants · Participants
Number of Participants Experiencing Adverse Events (AEs)
ParticipantsDose Level 1a: 0.1 mg/kgDose Level 1b: 0.3 mg/kgDose Level 2: 0.5 mg/kgDose Level 3: 0.75 mg/kgDose Level 4: 1 mg/kg
Participants with at least one TEAE898129
TEAE leading to dose interruption25425
Participants with at least one serious TEAE33333
Participants with at least one grade 2/3/4 TEAE796119
Participants with at least one drug-related grade 2/3/4 TEAE43477
Participants with at least one serious drug- related TEAE21101
Participants with at least one TEAE leading to sotatercept withdrawal30235
SecondaryConcentrations of Sotatercept in Serum

Sotatercept was administered as a subcutaneous injection every 21 days during the Treatment Period. Pharmacokinetic (PK) samples were collected at the pre-specified timepoints.

Time frame:
Dose 1, Day 8; Dose 1, Day 15; Dose 2, Day 1; Dose 2, Day 8; Dose 3, Day 1; Dose 3, Day 8; Dose 4, Day 1; Dose 5, Day 1; Dose 6, Day 1
Reported as:
Median · ng/mL
Concentrations of Sotatercept in Serum
ng/mLDose Level 1a: 0.1 mg/kgDose Level 1b: 0.3 mg/kgDose Level 2: 0.5 mg/kgDose Level 3: 0.75 mg/kgDose Level 4: 1 mg/kg
Dose 1, Day 8598.3 (289.2 to 1345.4)1454.05 (1006.6 to 2768.3)3045.45 (1586.7 to 4480)5837.65 (3238.1 to 10590.5)3874 (2264.9 to 7003)
Dose 1, Day 15388.7 (98.4 to 1046)1150.1 (550.3 to 2158.4)2329.75 (952 to 3005.5)4279.65 (2107.8 to 6692)2405.6 (1825.3 to 4605.5)
Dose 2, Day 1294.75 (112.9 to 547.1)770.3 (317.2 to 1300.1)1468.05 (682 to 2550.5)2955.2 (1257.5 to 4450.8)1701.5 (888.6 to 4267.9)
Dose 2, Day 8683.1 (250.1 to 1210.6)2065 (1363.7 to 3626.4)4136.8 (1661.9 to 5573.8)7753.35 (5046.4 to 8805.6)5148.1 (3537.4 to 10418.7)
Dose 3, Day 1325.35 (228.8 to 790)956.8 (380.6 to 1552.6)2157.3 (422 to 3088.4)3628.45 (653.5 to 6429.1)2602.6 (822.2 to 5668.1)
Dose 3, Day 8758.1 (444 to 1232)2319.9 (1475.6 to 3667.4)4507.3 (2077.8 to 5762.3)8373.05 (5345.5 to 12177.8)6050.8 (3892.5 to 12139.6)
Dose 4, Day 1334.85 (298 to 1014.9)1022.3 (348.8 to 2096.9)2441.6 (784 to 2845.3)4137.1 (1447.1 to 6126.6)2869.2 (1478.9 to 4787.7)
Dose 5, Day 1385.1 (287.5 to 467.5)1473.9 (762.1 to 2764.4)1618.8 (953.4 to 3440)4449.7 (2340.4 to 5887.8)3048 (1125.5 to 6529.3)
Dose 6, Day 1297.60 (227.80 to 484.40)1368.10 (449.70 to 2363.20)2266.40 (1115.20 to 3788.50)4062.80 (1481.10 to 6584.00)2780.80 (1479.20 to 7896.70)
SecondaryNumber of Participants With Anti-Drug Antibody (ADA)

The number of participants with Anti-Sotatercept Antibody is a summary of antidrug antibody (ADA) status for ADA-evaluated participants. A participant is counted as 'positive' if there is any positive result captured during the study, a participant is counted as 'negative' if there is no positive result captured during the study. ADA data was collected Day 1 in dose schedules 1 through 6. Starting from Dose 7, ADA was measured at Day 1 every 3 Doses, then finally at the post-treatment follow-up visit at Month 2 and Month 4.

Time frame:
From first dose up to 4 months after last dose (up to approximately 116 months)
Reported as:
Count of participants · Participants
Number of Participants With Anti-Drug Antibody (ADA)
ParticipantsDose Level 1a: 0.1 mg/kgDose Level 1b: 0.3 mg/kgDose Level 2: 0.5 mg/kgDose Level 3: 0.75 mg/kgDose Level 4: 1 mg/kg
Negative888109
Positive01020
SecondaryNumber of Participants Experiencing Quality of Life (QOL) Change From Baseline

The number of participants in the expansion cohort experiencing changes from baseline in Quality of Life. QOL was planned to be assessed at Day 168 (6 months) and Day 336 (12 months), after Dose 1 Day 1, independent of Dose Delay for participants enrolled in the Expansion Cohort only. QOL was planned to be calculated using the SF-36 and the FACT Anemia. The SF-36 is a Medical Outcomes Study (MOS) consisting of 36 questions developed to determine health status. The SF-36 measures eight scales: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The FACT Anemia measures fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) Measurement System. Due to early study termination, no participants were enrolled in the expansion cohort and QOL was not assessed.

Time frame:
From pre-dose up to Dose 8 (168 days/6months) and Dose 16 (336 days/12months) only

No measurements were reported for this outcome.

Adverse events

Collected over Participants were assessed for all-cause mortality from their enrollment to study completion, (up to approximately 115 months). SAEs and Other AEs were assessed from first dose to 112 days following last dose (up to approximately 115 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose Level 1a: 0.1 mg/kg0/8 (0%)3/8 (37.5%)8/8 (100%)
Dose Level 1b: 0.3 mg/kg0/9 (0%)3/9 (33.3%)9/9 (100%)
Dose Level 2: 0.5 mg/kg0/8 (0%)3/8 (37.5%)8/8 (100%)
Dose Level 3: 0.75 mg/kg0/12 (0%)3/12 (25%)12/12 (100%)
Dose Level 4: 1 mg/kg0/9 (0%)3/9 (33.3%)9/9 (100%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventDose Level 1a: 0.1 mg/kgDose Level 1b: 0.3 mg/kgDose Level 2: 0.5 mg/kgDose Level 3: 0.75 mg/kgDose Level 4: 1 mg/kg
ANAEMIABlood and lymphatic system disorders0/80/91/80/120/9
SPLENIC INFARCTIONBlood and lymphatic system disorders1/80/90/80/120/9
PERICARDIAL EFFUSIONCardiac disorders0/80/91/80/120/9
ABDOMINAL PAIN UPPERGastrointestinal disorders0/80/91/80/120/9
FATIGUEGeneral disorders0/80/91/80/120/9
LOCAL SWELLINGGeneral disorders0/80/91/80/120/9
PYREXIAGeneral disorders0/81/91/80/120/9
ANAPHYLACTIC REACTIONImmune system disorders0/80/91/80/120/9
LUMBAR VERTEBRAL FRACTUREInjury, poisoning and procedural complications0/80/91/80/120/9
BONE PAINMusculoskeletal and connective tissue disorders1/80/90/80/120/9
Most frequent other events
Showing 10 of 368
Most frequent other events
EventDose Level 1a: 0.1 mg/kgDose Level 1b: 0.3 mg/kgDose Level 2: 0.5 mg/kgDose Level 3: 0.75 mg/kgDose Level 4: 1 mg/kg
ARTHRALGIAMusculoskeletal and connective tissue disorders5/86/97/88/122/9
BACK PAINMusculoskeletal and connective tissue disorders3/87/96/85/123/9
HEADACHENervous system disorders2/86/95/89/123/9
PYREXIAGeneral disorders3/86/92/83/124/9
BONE PAINMusculoskeletal and connective tissue disorders4/86/94/84/124/9
RHINITISInfections and infestations1/83/95/81/121/9
PAIN IN EXTREMITYMusculoskeletal and connective tissue disorders3/83/95/85/123/9
COUGHRespiratory, thoracic and mediastinal disorders3/84/95/83/123/9
ABDOMINAL PAIN UPPERGastrointestinal disorders2/85/91/84/121/9
INFLUENZAInfections and infestations0/85/91/81/121/9

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Dose Level 1a: 0.1 mg/kgDose Level 1b: 0.3 mg/kgDose Level 2: 0.5 mg/kgDose Level 3: 0.75 mg/kgDose Level 4: 1 mg/kgTotal
Median39.5 ± 8.2140.0 ± 9.8938.5 ± 7.6344.0 ± 10.2941.0 ± 10.3639.5 ± 9.22
Sex: Female, Male
Sex: Female, Male(Participants)Dose Level 1a: 0.1 mg/kgDose Level 1b: 0.3 mg/kgDose Level 2: 0.5 mg/kgDose Level 3: 0.75 mg/kgDose Level 4: 1 mg/kgTotal
Female4438322
Male4554624
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dose Level 1a: 0.1 mg/kgDose Level 1b: 0.3 mg/kgDose Level 2: 0.5 mg/kgDose Level 3: 0.75 mg/kgDose Level 4: 1 mg/kgTotal
American Indian or Alaska Native000000
Asian100214
Native Hawaiian or Other Pacific Islander000000
Black or African American000000
White79610840
More than one race000000
Unknown or Not Reported002002
08

Study locations

18 sites
  • Hopital Henri Mondor
    Créteil, 94010, France
  • Groupe Hospitalier Henri Mondor
    Créteil, France
  • Hospital of Necker
    Paris, 75015, France
  • Local Institution - 001
    Paris, 75015, France
  • Hôpital Necker-Enfants Malades
    Paris, France
  • Local Institution - 300
    Ampelokipi - Athens, 115 26, Greece
  • Laiko General Hospital
    Ampelokipi - Athens, 11526, Greece
  • Universita degli Studi di Cagliari - ASL8
    Cagliari, 09121, Italy
  • Universita Degli Studi Di Cagliari
    Cagliari, 09121, Italy
  • Local Institution - 200
    Genoa, 16128, Italy
  • Ospedale Galliera
    Genoa, 16128, Italy
  • Ente Ospedaliero Ospedali Galliera
    Genova, 16128, Italy
  • Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
    Milano, 20122, Italy
  • Fondazione IRCCS Ospedale Maggiore
    Milano, 20122, Italy
  • Local Institution - 201
    Milano, 20122, Italy
  • Local Institution - 100
    London, WC1E 6BT, United Kingdom
  • UCL Cancer Institute
    London, WC1E 6BT, United Kingdom
  • UCL Cancer Institue
    London, WC1E6BT, United Kingdom
09

References and documents

Publications

  • Cappellini MD, Porter J, Origa R, Forni GL, Voskaridou E, Galacteros F, Taher AT, Arlet JB, Ribeil JA, Garbowski M, Graziadei G, Brouzes C, Semeraro M, Laadem A, Miteva D, Zou J, Sung V, Zinger T, Attie KM, Hermine O. Sotatercept, a novel transforming growth factor beta ligand trap, improves anemia in beta-thalassemia: a phase II, open-label, dose-finding study. Haematologica. 2019 Mar;104(3):477-484. doi: 10.3324/haematol.2018.198887. Epub 2018 Oct 18. PubMed 30337358 ↗
  • Cappellini M, et al. A Phase 2a, Open-Label, Dose-Finding Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta ( )-Thalassemia: Interim Results. Presented at the 55th Annual Meeting of the American Society of Hematology (ASH), December 7-10, 2013, New Orleans, LA. Abstract No. 3448
  • "Porter J, et al. Interim Results From a Phase 2A, Open-Label, Dose-Finding Study To Determine The Safety, Efficacy, And Tolerability of Sotatercept (ACE-001) In Adults with Beta-Thalassemia. Presented at the 19thCongress of the European Hematology Association, June 12-15, 2015, Milan, Italy. Abstract No. S622 "
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2012 to primary completion in Jul 2015, 32 months.

Results were first posted in Jun 2023, 7 years 11 months after primary completion. A results delay was requested in Dec 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2012
First posted
Apr 5, 2012
StartActual
Oct 10, 2012
Primary completionActual
Jul 2, 2015
CompletionActual
May 24, 2022
Results delay requested
Dec 11, 2015
Results first posted
Jun 18, 2023
Last update
Jun 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01571635
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Apr 5, 2012
Start date
Oct 10, 2012
Primary completion
Jul 2, 2015
Completion
May 24, 2022
Results posted
Jun 18, 2023
Last update
Jun 18, 2023

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sotatercept

Start the discussion